Literature DB >> 20014331

Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme.

Georgios A Dalkas1, Damien Marchand, Jean-Claude Galleyrand, Jean Martinez, Georgios A Spyroulias, Paul Cordopatis, Florine Cavelier.   

Abstract

Human ACE is a central component of the renin-angiotensin system and a major therapeutic target for cardiovascular diseases. The somatic form of the enzyme (sACE) comprises two homologous metallopeptidase domains (N and C), each bearing a zinc active site with similar but distinct substrate and inhibitor specificities. In this study, we present the biological activity of silacaptopril, a silylated analogue of captopril, and its binding affinity towards ACE. Based on the recently determined crystal structures of both the ACE domains, a series of docking calculations were carried out in order to study the structural characteristics and the binding properties of silacaptopril and its analogues with ACE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20014331     DOI: 10.1002/psc.1201

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  3 in total

1.  One-pot synthesis, biological evaluation, and docking study of new chromeno-annulated thiopyrano[2,3-c]pyrazoles.

Authors:  Bhagyashri D Parmar; Tushar R Sutariya; Gaurangkumar C Brahmbhatt; Narsidas J Parmar; Rajni Kant; Vivek K Gupta; Prashant R Murumkar; Mayank Kumar Sharma; Mange Ram Yadav
Journal:  Mol Divers       Date:  2016-03-26       Impact factor: 2.943

2.  Structural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captopril.

Authors:  Mohd Akif; Geoffrey Masuyer; Sylva L U Schwager; Bhaskar J Bhuyan; Govindasamy Mugesh; R Elwyn Isaac; Edward D Sturrock; K Ravi Acharya
Journal:  FEBS J       Date:  2011-09-08       Impact factor: 5.542

3.  Nickel(ii)-catalyzed reductive silylation of alkenyl methyl ethers for the synthesis of alkyl silanes.

Authors:  Xiaodong Qiu; Li Zhou; Haoran Wang; Lingyi Lu; Yong Ling; Yanan Zhang
Journal:  RSC Adv       Date:  2021-11-18       Impact factor: 3.361

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.